The major factors that boost the market growth include technological advancements in tissue and organ regeneration, increase in prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. In addition, rise in degenerative diseases and shortage of organs for transplantation are expected to fuel the growth of the market. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened numerous growth avenues for the regenerative medicines market. However, stringent regulatory barriers and high cost of the treatment are likely to hinder the market growth.
The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and LAMEA.
KEY MARKET BENEFITS FOR STAKEHOLDERS
This report offers a detailed quantitative analysis of the market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on a comprehensive analysis of the key developments in the industry.
An in-depth analysis based on geography facilitates the study of the regional market to assist in strategic business planning.
The development strategies adopted by the key manufacturers are enlisted in the report to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Product Type
Cell Therapy
Gene Therapy
Tissue Engineering
Small Molecule & Biologic
By Material
Synthetic Material
Biodegradable Synthetic Polymer
Scaffold
Artificial Vascular Graft Material
Hydrogel Material
Biologically Derived Material
Collagen
Xenogeneic Material
Genetically Engineered Material
Deoxyribonucleic Acid Transfection Vectors
Genetically Manipulated Cell
Three-Dimensional Polymer Technology
Transgenic
Fibroblast
Neural Stem Cell
Gene-Activated Matrices
Pharmaceuticals
Small Molecule
Biologic
By Application
Cardiovascular
Oncology
Dermatology
Musculoskeletal
Wound Healing
Ophthalmology
Neurology
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Russia
Netherlands
Sweden
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
Singapore
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA
KEY PLAYERS PROFILED
Stryker Corporation
Zimmer Biomet Holdings, Inc.
Medtronic Plc.
Athersys, Inc.
U.S. Stem Cell, Inc. (Bioheart, Inc.)
Organogenesis, Inc. (Advanced Biohealing)
Integra Lifesciences Holdings Corporation
Acelity Holdings, Inc.
Isto Biologics (Isto Biologics Medical Systems, Inc.)
CryoLife, Inc.
The other players of the Regenerative Medicine market include (companies not profiled in the report):
Shimadzu Recursion Pharmaceuticals, Inc.
Baxter International, Inc.
DePuy Synthes
Siemens Healthineers
General Electric (GE) Company
Koninklijke Philips N.V.
Cloudmedx, Inc.
Bay Labs, Inc.
What is the estimated value of the Global Regenerative Medicine Market?
What is the growth rate of the Global Regenerative Medicine Market?
What is the forecasted size of the Global Regenerative Medicine Market?
Currently, majority of the available treatments for degenerative or life-threatening diseases do not provide a cure or are palliative; however, regenerative medicines have the capability to replace or regenerate the tissues and organs that are injured or diseased. Moreover, the utilization of nanomaterials in wound care, drug delivery, and immunomodulation create growth opportunities for the regenerative medicines market.
The major factors boosting the market growth include technological advancements in tissue and organ regeneration, increasing prevalence of chronic diseases and trauma emergencies, prominent potential of nanotechnology, and emergence of stem cell technology. Moreover, utilization of nanomaterials in wound care, drug delivery, and immunomodulation has opened growth avenues for the regenerative medicine market. However, stringent regulations, operational inefficiency, and high cost of regenerative medicine treatment are the key factors affecting the market growth. Furthermore, advancements in stem cell technology and achieving core competency in the emerging economies are expected to fuel the market growth. Developed nations have adopted technological advancements in tissue engineering and regenerative medicine sectors, which would aid the expansion of the global market.
The cell therapy segment accounted for a significant share of about three-fifth the overall regenerative medicine market in 2016 due to the widespread adoption of cell therapy for treatment of several diseases such as musculoskeletal, cardiovascular, oncology, wound healing, and others. Small molecules and biologics has emerged as the fastest growing segment during the forecast period as these biologics are classic active substances delivering better overall economic return. These molecules have revolutionized the treatment of specific diseases such as musculoskeletal diseases, cancer, rheumatoid arthritis, and non-healing wounds.
Musculoskeletal and wound healing segment accounted for about three-fifth share of the application market in 2016. Cell therapies are used in the treatment of musculoskeletal diseases such as bone tissue replacement, cartilage, tendon, and ligament repair and replacement. In addition, osteoporosis is one of the most prevalent diseases that require tissue engineering therapies. More than 75 million people suffer from osteoporosis in Europe, the U.S., and Japan every year, which boosts the demand for regenerative medicines.
Geographically, North America accounted for majority of the share of the overall regenerative medicine market in 2016, and is expected to maintain this trend during the forecast period. This is attributed to high capital investment, high disposable income of patients, numerous clinical studies, and favorable government policies for the commercialization of tissue engineering and regenerative medicine products. However, Asia-Pacific is projected to be the fastest growing region throughout the analysis period due to the improving healthcare infrastructure and healthcare expenditures in the emerging markets, such as India and China, to overcome the unmet medical needs in these countries.
Key findings of the Regenerative Medicine Market:
Small molecules and biologics segment is projected to grow at the highest rate among the product type segment during the analysis period.
North America dominated global regenerative medicine market in 2016, and is projected to continue its dominance in future.
China is expected to grow at the highest rate in the Asia-Pacific region during the forecast period.
Biologically derived materials segment was the largest contributor among the material segments in 2016.
The synthetic materials segment generated the highest revenue, and is expected to continue its dominance in future.
The key players operating in the global regenerative medicine market include Stryker Corporation, Zimmer Biomet Holdings, Inc., Medtronic Plc., Athersys, Inc., U.S. Stem Cell, Inc. (Bioheart, Inc.), Organogenesis, Inc. (Advanced Biohealing), Integra Lifesciences Holdings Corporation, Acelity Holdings, Inc., Isto Biologics (Isto Biologics Medical Systems, Inc.), and CryoLife, Inc. Other prominent players in the value chain include Shimadzu Recursion Pharmaceuticals, Inc., Baxter International, Inc., DePuy Synthes Siemens Healthineers, General Electric (GE) Company, Koninklijke Philips N.V., Cloudmedx, Inc., and Bay Labs, Inc.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...